Wednesday, March 3, 2021
Serving the Residents of Las Vegas, Nevada and Clark County

Leonhardt’s Launchpads Announces Receipt of Notice of Allowance of U.S. Patent for Bioelectric Stimulator for Organ Regeneration and Healing

United States, California, Irvine – 10-05-2020 ( — Irvine, California, October 6th, 2020 /PRDistribution/ — Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc.  a California headquartered…

By Editorial Team , in PR , at October 6, 2020

United States, California, Irvine – 10-05-2020 ( — Irvine, California, October 6th, 2020 /PRDistribution/ — Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc.  a California headquartered innovation accelerator focused on organ regeneration technologies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. US15/812,760 US201662308702P originally filed March 15th, 2016.  The patent, exclusively licensed and assigned to Leonhardt’s Launchpads and all its organ specific portfolio startups (31), is owned by Leonhardt Ventures LLC from inventors Howard J. Leonhardt and Dr. Jorge Genovese.

Here is a link to Leonhardt’s Launchpads 2020 portfolio of organ specific innovations and startups that will utilize this patented technology in developing new products

The bioelectric stimulator invention focuses on precise signaling sequences for control of release of key candidate regeneration and healing proteins derived from stimulating a patient’s own body tissues and organs.  The goal is to help the body regenerate itself by extending, amplifying and enhancing natural bioelectric healing signals and protein expressions including stem cell homing, proliferation and differentiation control. 

The method and device claims of the patent cover the use of bioelectric stimulation for organ regeneration and healing including heart, brain, aorta, heart valves, lungs, kidney, pancreas, liver, bladder, bone, inflammation, cancer, gut micro biota health, testosterone and infertility management, immune system disorders, essential tremors, blood pressure-hypertension, dental, orthodontic, orthopedic, breast, skin, hair, erectile dysfunction, eye vision and ear hearing applications of use. 

“The era of bioelectric and biologics based organ regeneration and healing is upon us and Leonhardt’s Launchpads is proud to be leading with the way with over 600 patent claims and many hundreds of patients enrolled in clinical evaluations to date” stated Howard J. Leonhardt, Executive Chairman & CEO and primary inventor.   

“Our team has been working for over three decades on perfecting bioelectric and biologics based healing technologies.  This patent is a culmination of that work. We started with research work on regenerating damaged heart tissue and treating lower limb ischemia and now have expanded to over 30 potential indications of use of this core platform IP.”  stated Dr. Jorge Genovese Vice President of Bioelectric Regeneration Research at Leonhardt’s Launchpads, co-Inventor and former researcher at the McGown Regenerative Medicine Institute in Pittsburgh and Director of the Cardiac Regeneration Laboratory at the University of Utah. 

CAUTION:  All devices and therapies mentioned are in early stage development and are not yet proven either safe or effective and are not available or offered for sale.  They are investigational devices and biologics and are limited by Federal (or United States) law and applicable foreign regulations to investigational use only, where available at all.  Many applications are still only in pre-clinical evaluation. 

The bioelectric stimulator patent also covers non-medical uses such as improving fish aquaculture, improving milk production from cows with less hormones and improving cattle meat quality with less hormones. 

March of 2019 the Leonhardt team announced the filing a pioneering patent application covering bioelectric stimulation controlled klotho release which will integrated into this patented bioelectric stimulator technology.  Klotho has been identified in independent studies to have high potential to help treat many different diseases associated with aging. 

Separately the Leonhardt team has exclusively licensed 9 issued patents for bioelectric treatment of cancer from the late Eleanor Schuler 

About Leonhardt’s Launchpads and Leonhardt Ventures LLC: 
Leonhardt’s Launchpads  is an Irvine, California headquartered innovation and startup launch accelerator focused on applying a common core intellectual property estate in bioelectrics and biologics to organ regeneration and healing.  Leonhardt’s Launchpads is the innovation and startup launch accelerator arm of Leonhardt Ventures LLC which has a non-dilutive 50.1% controlling ownership position.  The Leonhardt team patented and developed the PolyCath cardiovascular balloon catheter line in the 1980s, the TALENT stent graft for aortic aneurysm repair and StentValve percutaneous heart valve in the 1990’s and in 2001 led the team that completed the landmark first non-surgical cell based repair of a human heart.  Since 1988 the team has focused on applying bioelectrics and biologics to organ regeneration and healing. R&D Labs are located in California and Utah (2) with research branch affiliates in Pittsburgh, Santa Rosa, Minneapolis, Brazil, The Netherlands and Australia. 

Like to 2019/20 Annual Report >

Forward-Looking Safe Harbor Statement: 
This press release contains forward-looking statements, including but not limited to, research and development outcomes, efficacy, adverse reactions, market and product potential, product availability and other statements regarding technologies.  These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Timeleins could be extended by many years even decades.  Patents pending may not be issued.  Patents issued may not be maintained. Early study results may not be confirmed in larger scale statistically significant controlled studies.  Information on linked to web sites is subject to being out dated.  Risks and uncertainties include, among other things, general industry and medical device market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new medical device products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations.  


Howard J. Leonhardt, Executive Chairman & CEO, 

Brian Hardy, Director of Marketing,

Web site: 

Addresses of offices and R&D labs:

Google Voicemail:  Phone: (424) 291-2133

Fax: (866) 829-0929

SOURCE:  Leonhardt Ventures LLC and Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. 

Media Contacts:

Company Name: Leonhardt’s Launchpads
Full Name: Howard J. Leonhardt
Phone: (424) 291-2133
Email Address: Send Email

For the original news story, please visit